Overview
- Lilly’s tirzepatide franchise, sold as Mounjaro and Zepbound, remains the primary growth engine with 100%+ year-over-year gains and more than $10 billion in recent quarterly sales.
- Analysts report a strategic pivot toward prioritizing volume and access over net price for obesity treatments to broaden reach and sustain adoption.
- Recent quarterly results beat expectations, with revenue up 10% versus consensus, EPS up 19%, operating margin expanding from 40% to 48%, and cash from operations rising to $8.8 billion.
- Late-stage assets including orforglipron and retatrutide, along with oral GLP-1 candidates and deals with Nimbus and Superluminal, are cited as diversifiers of future revenue.
- Despite a premium P/E, some analysts point to a supportive PEG ratio and strong momentum, while cautioning about potential multiple compression and competitive and payer pressures.